Home
About
Overview
Management Team
Board of Directors
Medical Advisory Board
Product Pipeline
Overview
Nyxol
APX3330
APX2009
Posters and Publications
Clinical Trials
Overview
VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia
Enrolling
ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330
Last Patient Last Visit Completed
MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
Completed
MIRA-3
Completed
MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol
Completed
LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol
Completed
VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine
Completed
Partnerships
News & Media
Press Releases
Presentations
Events
Ocuphire in the News
Investors
Overview
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Contact
Careers
Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances
For more details,
click here for the full news release.
Continue
Ocuphire in the News
News & Media
News & Media
Press Releases
Presentations
Events
Ocuphire in the News
Presbyopia: How are the Drops Performing?
Jul 10, 2022
Presbyopia-correcting drops broaden options for younger patients
Jul 1, 2022
So Many Options Coming! What Differences Do We See So Far?
Jun 1, 2022
Ocuphire Pharma's Mina Sooch
May 1, 2022
Ophthalmology Management eUpdate
Mar 9, 2022
Presbyopia Physician March 2022
Mar 1, 2022
The Latest Roundup of Key Presbyopia Correcting Drops
Feb 1, 2022
What Is the Optimal Pupil Size?
Jan 18, 2022
Presbyopia Physician November 2021
Nov 15, 2021
Highlights from American Academy of Ophthalmology Conference 2021
Nov 13, 2021
« Previous
1
2
3
4
Next »